darrow red | 15391-59-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: darrow red
• 英文别名: N-(5-iminobenzo[a]phenoxazin-9-yl)acetamide
• CAS: 15391-59-0
• 化学式: C₁₈H₁₃N₃O₂
• 分子量: 303.32
• InChiKey: RBWQBBLNRPWMBM-UHFFFAOYSA-N

物化性质

• 溶解度：
  易溶于水、乙醇
• 最大波长(λmax)：
  502 nm

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  74.5
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  darrow red 在 manganese(IV) oxide 、 吡啶盐酸盐 、 锌 作用下， 以 乙二醇 为溶剂， 反应 5.0h， 生成 N-((5e)-5-(pyridin-4-ylimino)-5h-benzo[a]phenoxazin-9-yl)acetamide
  参考文献：
  名称：

  JP5773123

  摘要：

  公开号：

文献信息

• Novel synthetic route for antimalarial benzo[a]phenoxazine derivative SSJ-183 and two active metabolites
  作者：Yuki Mizukawa、Jian-Feng Ge、Abu Bakar Md、Isamu Itoh、Christian Scheurer、Sergio Wittlin、Reto Brun、Hiroyuki Matsuoka、Masataka Ihara

  DOI：10.1016/j.bmc.2014.04.066

  日期：2014.7

  A productive synthesis of benzo[a]phenoxazine derivative SSJ-183 (1), a promising lead for antimalarial agents, was developed using a one pot procedure. Furthermore, N-deethylated metabolite 3 and bis-N,N-deethylated metabolite 4 were synthesized by the application of the method. The metabolites 3 and 4 showed comparable and ∼2-fold increased activities against drug-sensitive and drug-resistant Plasmodium falciparum parasites.
• Molecular Resist Compositions, Methods of Patterning Substrates Using the Compositions and Process Products Prepared Therefrom
  申请人：MCLELLAN Joseph M.

  公开号：US20090311484A1

  公开（公告）日：2009-12-17

  The present invention is directed to molecular resist compositions comprising an organic amine, methods of forming features on substrates using the molecular resists compositions and process products prepared therefrom.
• Compositions and methods for bone formation and remodeling
  申请人：Wu Dianqing (Dan)

  公开号：US20100298308A1

  公开（公告）日：2010-11-25

  The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 that is required for the coreceptors' transport to cell surfaces, resulting in less LRP5 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm. Together with the observation that osteoblast cells produce autocrine canonical Wnt, Wnt7b, and that osteocytes produce paracrine Dkk1, we believe that the G171V mutation may cause an increase in Wnt activity in osteoblasts by reducing the number of targets for paracrine Dkk1 to antagonize without affecting the activity of autocrine Wnt.
• COMPOSITIONS AND METHODS FOR BONE FORMATION AND MODELING
  申请人：ENZO Biochem, Inc.

  公开号：US20130172332A1

  公开（公告）日：2013-07-04

  The present disclosure is directed to methods of identifying a compound that binds to or interacts with a protein receptor involved in bone formation. Specifically, the disclosure is directed to methods of identifying a compound that regulates a Wnt pathway in a cell by binding to or interacting with cavities in proteins such as LRP5, LRP 6 and/or frizzled receptor and interfering with receptor binding to other proteins in a Wnt pathway. The present disclosure is further directed to methods and compositions that comprise an identified compound for treating or preventing a disease in a mammal in which Wnt pathway suppression plays a role.
• US8367822B2
  申请人：——

  公开号：US8367822B2

  公开（公告）日：2013-02-05